New Delhi, April 17 -- Cipla's shares have surged 6% since saying last week it received final approval from the US Food and Drug Administration for its generic version of Bristol Myers Squibb's Abraxane, a cancer drug.

Does the approval to sell the much-awaited product in the US make Cipla a compelling buy, especially when Trump's tariffs are looming on the horizon?

"One product approval by itself doesn't suddenly make a company more attractive," said Prashant Nair, lead analyst for pharma and healthcare at Ambit Capital. "Earlier-than-expected approval for Abraxane is positive, but tariffs will have a bearing on Cipla."

The extent of the impact of tariffs would depend on the quantum of the levy, the company's efforts to scale up suppl...